8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)-Reference-Cited by-同舟云学术

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Published:2019-03 Issue:3 Volume:70 Page:554-557
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Boerekamps Anne^ORCID,Vanwolleghem Thomas,van der Valk Marc,van den Berk Guido E.,van Kasteren Marjo,Posthouwer Dirk,Dofferhoff Anthonius S.M.,van Hoek Bart,Ramsoekh Dewkoemar,Koopsen Jelle,Schinkel Janke,Florence Eric,Arends Joop E.,Rijnders Bart J.

Funder

Foundation Against Cancer Belgium

Gilead Sciences,

Bristol-Myers-Squibb

Abbvie

Janssen Pharmaceuticals

ViiV Healthcare

Publisher

Elsevier BV

Subject

Hepatology

Reference11 articles.

1. Hepatitis C genotype 4: the past, present, and future;Abdel-Ghaffar;World J Hepatol,2015

2. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis;Iyengar;PLoS Med,2016

3. WHO Global health sector strategy on viral hepatitis 2016-2021. Available from: http://appswhoint/iris/bitstream/10665/246177/1/WHO-HIV-201606-engpdf 2017.

4. Eliminating hepatitis C within low-income countries – the need to cure genotypes 4, 5, 6;Asselah;J Hepatol,2018

5. EASL Recommendations on Treatment of Hepatitis C 2018;European Association for the Study of the Liver;J Hepatol,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of 8-Week Daclatasvir-Sofosbuvir Regimen in Chronic Hepatitis C: A Systematic Review and Meta-Analysis;2024-09-12

2. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection;Journal of Clinical Medicine;2022-01-13

3. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?;Viruses;2022-01-06

4. Biobanking for Viral Hepatitis Research;Frontiers in Medicine;2019-08-20

5. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update;Clinical Pharmacokinetics;2019-05-21